Seattle Genetics is looking for a PharmD Fellow to join its US Commercial Marketing group. The objective of the Seattle Genetics PharmD fellowship program is to provide pharmacists with hands-on commercial experience to complement their clinical training. The 1-year training program is meant to serve as a strong foundation for a career within the pharmaceutical industry.
The fellow will assist and lead a variety of projects within the Marketing group while interacting with personnel from Sales, Market Planning, Managed Markets as well as key cross-functional groups including Medical Affairs, Regulatory Affairs, and Clinical Development. The fellow will also have opportunities to participate in strategic marketing initiatives, including the development of brand and tactical plans.
The role will primarily support key US marketing activities associated with the promotion of ADCETRIS (brentuximab vedotin). ADCETRIS is an antibody-drug conjugate (ADC) directed to the CD30 antigen using Seattle Genetics' proprietary ADC technology. It comprises an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in target cell death. ADCETRIS® (brentuximab vedotin) is approved for two types of lymphoma in more than 71 countries, including the U.S., Canada, Japan and members of the European Union.
Manage the development and execution of select branded and unbranded promotional materials
Coordinate key logistical activities, notably those related to the promotional review committee, promotional material fulfillment, and national congress planning
Summarize key insights from emerging clinical data in the oncology space to inform projects and initiatives within the commercial organization
Manage advertising agencies and other commercial vendors
Develop and deliver presentations as needed to the marketing team and other internal groups
Work collaboratively with all internal/external partners and stakeholders
Travel may include, but is not limited to, attendance at key sales and marketing meetings, as well as attendance at annual ASCO, ASH, and ASHP meetings
A Doctor of Pharmacy degree from an ACPE accredited institution
Relevant Internship or Clerkship experience
Oncology experience is a plus
Strong interpersonal communication skills
Evidence of good communication, analytical, planning and organizational skills
Basic knowledge of the pharmaceutical industry including Product Development, Manufacturing, Regulatory, Medical Affairs, and Commercial operations
Possess good communication skills, including oral, written, and presentation
Ability to thrive in a fast-paced, dynamic environment
Must be willing to travel
Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.
Application deadline is Friday, November 30th, 2018. No references necessary until final onsite interview at Seattle Genetics.
About Seattle Genetics
Seattle Genetics is an emerging multi-product, global biotechnology company and the largest based in the Pacific Northwest. We develop and commercialize transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is approved for the treatment of multiple CD30-expressing lymphomas.
Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.
With multiple global product opportunities, significant research into advancing ADC technology and an emerging complementary immuno-oncology technology, we are positioned to transform cancer therapy.